Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Share News (CSRT)

  • There is currently no data for CSRT

Consort backs diagnostics firm

Mon, 07th Feb 2011 13:46
Drug inhaler firm Consort Medical has formed a strategic alliance with Atlas Genetics, a UK-based healthcare technology company with a point of care (POC) diagnostics platform.Consort's Bespak division will undertake design for manufacture work to prepare the disposable test cards that are a core component of the Atlas system and has also been awarded long term manufacturing rights for the card.Consort is taking a 19.5% stake in Atlas at a cost of £1.1m, and has agreed to invest further £0.4m in Atlas by the end of March 2012. Under the terms of the deal Atlas will grant Consort a non-executive seat on the board."Atlas's technology has the potential to revolutionise the testing and treatment of infectious diseases and we believe that the combination of our manufacturing scale and expertise to their technological strength will offer a compelling solution," said Consort's chief executive officer, Jon Glenn.

Related News

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition
17 Feb 2020

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition

Monday broker round-up
10 Feb 2020

Monday broker round-up

(Sharecast News) - Consort Medical: RBC Capital Markets upgrades to sector performer with a target price of 1,010p.

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional
4 Feb 2020

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional

CSRT.L News

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition
17 Feb 2020

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition

Monday broker round-up
10 Feb 2020

Monday broker round-up

(Sharecast News) - Consort Medical: RBC Capital Markets upgrades to sector performer with a target price of 1,010p.

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional
4 Feb 2020

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional

Recipharm To Make No Further Changes To Consort Medical Offer
29 Jan 2020

Recipharm To Make No Further Changes To Consort Medical Offer

Recipharm To Make No Further Changes To Consort Medical Offer

Recipharm Extends Consort Medical Offer Deadline To February 4
24 Jan 2020

Recipharm Extends Consort Medical Offer Deadline To February 4

Recipharm Extends Consort Medical Offer Deadline To February 4

Recipharm Buys 10% Of Takeover Target Consort Medical
22 Jan 2020

Recipharm Buys 10% Of Takeover Target Consort Medical

Recipharm Buys 10% Of Takeover Target Consort Medical

Recipharm's Consort Medical Takeover Clears German Regulatory Hurdle
14 Jan 2020

Recipharm's Consort Medical Takeover Clears German Regulatory Hurdle

Recipharm's Consort Medical Takeover Clears German Regulatory Hurdle

Friday broker round-up
10 Jan 2020

Friday broker round-up

(Sharecast News) - Polymetal International: Berenberg upgrades to buy with a target price of 1,480p.